Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 3:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2665–2688 of 2,912 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Endometriosis Related Pain
Interventions: Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 43
States / cities: Dothan, Alabama • Mesa, Arizona • Scottsdale, Arizona + 37 more

Conditions: Oral Leukoplakia
Interventions: Pioglitazone hydrochloride, placebo, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 11
States / cities: Birmingham, Alabama • Iowa City, Iowa • Boston, Massachusetts + 6 more

Conditions: Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
Interventions: ORMD-0801 (Insulin) capsule 8 mg BD, Placebo; Drug · Other
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Tustin, California

Conditions: Overactive Bladder
Interventions: PTNS plus solifenacin, Placebo; Other
Lead sponsor: Bay State Clinical Trials, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Watertown, Massachusetts

Conditions: Alcoholism, Alcohol Abuse, Alcohol Dependence
Interventions: Dutasteride, Placebo; Drug
Lead sponsor: UConn Health; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Generalized Anxiety Disorder (GAD)
Interventions: ABBV-932, Placebo for ABBV-932, Antidepressant Therapy (ADT); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 49
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 43 more

Conditions: Advanced Metastatic Breast Cancer
Interventions: Ribociclib, Tamoxifen, Letrozole, Anastrozole, Goserelin, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 59 Years · Female only
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 35
States / cities: Bakersfield, California • Los Angeles, California • Denver, Colorado + 29 more

Conditions: Respiratory Viral Infection
Interventions: zinc-green tea extract-ascorbic acid, Placebo; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Incident Breast Cancer
Interventions: tea capsule; Dietary Supplement
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sickle Cell Disease
Interventions: Placebo, HQK-1001; Drug
Lead sponsor: HemaQuest Pharmaceuticals Inc.; Industry
Eligibility: 12 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 8
States / cities: Madison, Alabama • Oakland, California • Daytona Beach, Florida + 5 more

Conditions: Pre Diabetes, Impaired Glucose Tolerance, Insulin Sensitivity, Insulin Resistance, Glucose Metabolism Disorders, Metabolic Syndrome
Interventions: Eubacterium hallii, Placebo; Dietary Supplement · Other
Lead sponsor: Atlantia Food Clinical Trials; Industry
Eligibility: 21 Years to 69 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atrial Fibrillation or Flutter
Interventions: Vanoxerine HCl, Placebo; Drug
Lead sponsor: Laguna Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 4
States / cities: Littleton, Colorado • Washington D.C., District of Columbia • Iowa City, Iowa + 1 more

Conditions: Hyperlipidemia
Interventions: FishOil, CBE75, CBE150, placebo; Dietary Supplement
Lead sponsor: MetaProteomics LLC; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Gig Harbor, Washington

Conditions: Metastatic Breast Cancer
Interventions: Veliparib Placebo, Veliparib, Carboplatin, Paclitaxel; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 56
States / cities: Gilbert, Arizona • Little Rock, Arkansas • Duarte, California + 48 more

Conditions: Rheumatoid Arthritis
Interventions: INCB028050, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 41
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 38 more

Conditions: Immune System Disorder (Healthy Volunteer)
Interventions: Belumosudil mesylate, Placebo; Drug
Lead sponsor: Kadmon, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Aging
Interventions: Probiotic capsule and Fiber Sachet, Probiotic capsule and Placebo sachet, Placebo capsule and Fiber Sachet, Placebo capsule and Placebo sachet; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 65 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 2
States / cities: Gainesville, Florida • Ocala, Florida

Conditions: COVID-19
Interventions: FoTv; Drug
Lead sponsor: Gordon Saxe; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Los Angeles, California • San Diego, California

Conditions: Chronic Pain Following Thermal Burn Injury
Interventions: Omega-3 fatty acids (fish oil), Vitamin D3 (cholecalciferol), Vitamin D3 (cholecalciferol) placebo, Omega-3 fatty acid placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy
Interventions: larazotide acetate; Drug
Lead sponsor: 9 Meters Biopharma, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Mild Cognitive Impairment
Interventions: Phosphatidylserine, Placebo; Other
Lead sponsor: Enzymotec; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 13
States / cities: Encino, California • Los Alamitos, California • Newport Beach, California + 10 more

Conditions: Fracture Lower Leg, Diabetes, Fracture Fixation, Internal
Interventions: Cefadroxil 500 mg Capsules, Clindamycin, Bactrim DS; Drug
Lead sponsor: Texas Tech University Health Sciences Center, El Paso; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • El Paso, Texas

Conditions: Primary Open Angle Glaucoma
Interventions: GlaucoCetin, Placebo; Dietary Supplement · Other
Lead sponsor: Wills Eye; Other
Eligibility: 40 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Euvolemic Hyponatremia
Interventions: Lixivaptan, Placebo; Drug
Lead sponsor: CardioKine Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 66
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 54 more

Search by objective public record fields.

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Pioglitazone for Oral Premalignant Lesions

A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)

Use of Percutaneous Tibial Nerve Stimulation With Solifenacin or Placebo to Treat Refractory Overactive Bladder

Dutasteride for the Reduction of Alcohol Use in Male Drinkers

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Zinc and Green Tea Extract for Community Respiratory Viral Infections

Green Tea in Breast Cancer Patients

Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease

Efficacy and Safety of 12-weeks Supplementation of Eubacterium Hallii on Insulin Sensitivity and Glycaemic Control

Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm

Effect of Citrus Bioflavonoids/Vitamin E in Conjunction With Fish Oil Supplementation

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs

A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects

The Effects of a High Protein Diet on Microbiota, Gastrointestinal Function and Wellness in Older Women

RCT of Fomitopsis Officinalis and Trametes Versicolor to Treat COVID-19

Vitamin D and n-3 Polyunsaturated Fatty Acids (PUFAs) to Prevent Chronic Pain Following Major Thermal Burn Injury

Safety of Larazotide Acetate in Healthy Volunteers

Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment

Extended Oral Antibiotic Prophylaxis in Diabetic Fracture Patients

Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia